Cytomx Therapeutics Stock Target Price
| CTMX Stock | USD 2.52 0.12 5.00% |
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess CytomX Therapeutics' long-term financial health and intrinsic value.
CytomX | Target Price | Build AI portfolio with CytomX Stock |
CytomX Target Price Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses CytomX Therapeutics' direct or indirect competition against its Target Price to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of CytomX Therapeutics could also be used in its relative valuation, which is a method of valuing CytomX Therapeutics by comparing valuation metrics of similar companies.CytomX Therapeutics is currently under evaluation in target price category among its peers.
CytomX Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of CytomX Therapeutics from analyzing CytomX Therapeutics' financial statements. These drivers represent accounts that assess CytomX Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of CytomX Therapeutics' important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 302.3M | 277.8M | 105.2M | 114.4M | 87.0M | 82.6M | |
| Enterprise Value | 135.3M | 90.3M | (70.4M) | 111.2M | 58.3M | 55.4M |
CytomX Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, CytomX Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to CytomX Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
CytomX Fundamentals
| Return On Equity | -54.75 | ||||
| Return On Asset | 0.16 | ||||
| Profit Margin | 0.28 % | ||||
| Operating Margin | 0.44 % | ||||
| Current Valuation | 306.37 M | ||||
| Shares Outstanding | 157.54 M | ||||
| Shares Owned By Insiders | 0.82 % | ||||
| Shares Owned By Institutions | 51.06 % | ||||
| Number Of Shares Shorted | 17.73 M | ||||
| Price To Earning | (11.41) X | ||||
| Price To Book | 15.09 X | ||||
| Price To Sales | 2.56 X | ||||
| Revenue | 138.1 M | ||||
| Gross Profit | 147.56 M | ||||
| EBITDA | 25 M | ||||
| Net Income | 31.87 M | ||||
| Cash And Equivalents | 194.29 M | ||||
| Cash Per Share | 2.94 X | ||||
| Total Debt | 9.38 M | ||||
| Debt To Equity | 0.67 % | ||||
| Current Ratio | 2.05 X | ||||
| Book Value Per Share | 0.31 X | ||||
| Cash Flow From Operations | (86.23 M) | ||||
| Short Ratio | 1.92 X | ||||
| Earnings Per Share | 0.48 X | ||||
| Price To Earnings To Growth | (1.80) X | ||||
| Target Price | 5.5 | ||||
| Number Of Employees | 119 | ||||
| Beta | 1.11 | ||||
| Market Capitalization | 378.11 M | ||||
| Total Asset | 120.53 M | ||||
| Retained Earnings | (691.58 M) | ||||
| Working Capital | 21.53 M | ||||
| Current Asset | 189.75 M | ||||
| Current Liabilities | 15.74 M | ||||
| Net Asset | 120.53 M |
About CytomX Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze CytomX Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of CytomX Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of CytomX Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for CytomX Stock Analysis
When running CytomX Therapeutics' price analysis, check to measure CytomX Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CytomX Therapeutics is operating at the current time. Most of CytomX Therapeutics' value examination focuses on studying past and present price action to predict the probability of CytomX Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CytomX Therapeutics' price. Additionally, you may evaluate how the addition of CytomX Therapeutics to your portfolios can decrease your overall portfolio volatility.